Coinfection of Hepatitis B and C with Human Immunodeficiency Virus in Hemophilia: A Cross Sectional Study

Main Article Content

T. S. Espósito
T. M. M. Paz
L. O. W. Rodrigues
A. C. A. Santos
R. D. M. Almeida
O. F. Santos
R. L. Medeiros
J. A. S. Lopes
D. O. W. Rodrigues

Abstract

Aims: To identify coinfection by Hepatitis B (HBV), Hepatitis C (HCV) and Human immunodeficiency virus (HIV) in Hemophiliacs.

Methodology: We included 107 hemophiliacs. For the current analysis, age, type, severity of Hemophilia and serum profile for Hepatitis B, C and HIV were included. The serological tests performed for Hepatitis and HIV were carried out using the enzyme-linked immunosorbent assay method (ELISA) and the confirmatory tests for HIV and HCV were done by the Western Blot and Polymerase Chain Reaction (PCR). The results of positive and negative serology were compared using the Mann-Whitney test using the Fundação Hemominas reproducibility map of serological reactions, through the CUT-off of each test.

Study Design: A cross-sectional study was carried out on hemophilics to asses the prevalence of infections diseases transmitted by transfusion.

Place and Duration of Study: Department of Hematology, public service on Coagulopathies at Fundação Hemominas Juiz de Fora Brazil, between January 2008 to December 2018.

Results: The average age was 32.77 years with standard deviation (SD)= 16.8 years. In regard to classification, 57.65% of patients with Hemophilia A were severe, and 57% of patients with Hemophilia B were moderate. Laboratory results demonstrated that 24.3% of the patients were HBV positive, and 40.2% were HCV positive, with 21.42% positive by PCR. The prevalence of HIV positive was 11.2%. In general analysis, 44.82% had at least one type of viral infection and 23.4% presented coinfections. HIV positive patients were all positive for HCV (11.2%) and 7.5% of patients were infected by HIV, HCV and HBV. The coexistence of hepatitis C and HIV was statistically relevant with (P = .001), considering the year of birth, most patients with HCV and HIV were born before 1980s (P = .001).

Conclusions: Infections by HBV, HCV and HIV are late complications in patients that received blood products before 1990s. Infection by a viral agent and the year of birth has a direct association, due to the standardization and implantation of tests for HIV and HCV in the 80s and 90s.

Keywords:
Hemophilia, hepatitis, HIV infection, transfusion, co-infection, treatment.

Article Details

How to Cite
Espósito, T. S., Paz, T. M. M., Rodrigues, L. O. W., Santos, A. C. A., Almeida, R. D. M., Santos, O. F., Medeiros, R. L., Lopes, J. A. S., & Rodrigues, D. O. W. (2020). Coinfection of Hepatitis B and C with Human Immunodeficiency Virus in Hemophilia: A Cross Sectional Study. Journal of Advances in Medicine and Medical Research, 32(17), 45-52. https://doi.org/10.9734/jammr/2020/v32i1730641
Section
Original Research Article

References

Berntorp E, Shapiro AD. Modern Hemophilia care. Lancet. 2012;379(9824): 1447-1456. DOI: 10.1016/S0140-6736(11)61139-2

Yeung CH, Santesso N, Pai M, et al. Care models in the management of Hemophilia: A systematic review. Hemophilia. 2016; 22(Suppl 3):31-40. DOI: 10.1111/hae.13000

Maor Y, Bashari D, Kenet G, et al. Hepatitis C at the israeli national hemophilia center. Hemophilia. 2006;12(1):68-74. DOI: 10.1111/j.1365-2516.2006.01178.x

Ferreira AA, Leite IC, Bustamante-Teixeira MT, et al. Health-related quality of life in hemophilia: Results of the hemophilia-specific quality of life index (Haem-a-Qol) at a Brazilian blood center. Rev Bras Hematol Hemoter. 2013;35(5):314-318. DOI:10.5581/1516-8484.20130108

Patek AJ, Taylor FH, Hemophilia II. Some properties of a substance obtained from normal human plasma effective in accelerating the coagulation of hemophilic blood. J Clin Invest. 1937;16(1):113-124. DOI: 10.1172/JCI100829.

Mehta P, Reddivari AKR. Hemophilia. [Updated 2020 Jun 10]. In: Stat Pearls [Internet]. Treasure Island (FL): Stat Pearls Publishing; 2020. Available:https://www.ncbi.nlm.nih.gov/books/NBK551607/

Fontes EM, Amorim L, Carvalho SM, Farah MB. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Publica. 2003;13(2-3):124-128. DOI: 10.1590/s1020-49892003000200013

Goedert JJ, Brown DL, Hoots K, et al. Human immunodeficiency and hepatits virus infections and their associated conditions and treatments among people with haemophilia. Haemophilia. 2004;10(4): 205–210.

Knight T, Callaghan MU. The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Hematol. 2018;9(10):319-334. DOI: 10.1177/2040620718799997 Published 2018 Oct 10.

Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia a without inhibitors. N Engl J Med. 2018;379(9):811-822. DOI: 10.1056/NEJMoa1803550

Machin N, Ragni MV. An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B. J Blood Med. 2018;9:135-140. DOI: 10.2147/JBM.S159297 Published 2018 Aug 22.

Buseri FI, Muhibi MA, Jeremiah ZA. Sero-epidemiology of transfusion-transmissible infectious diseases among blood donors in Osogbo, south-west Nigeria. Blood Transfus. 2009;7(4):293-299. DOI: 10.2450/2009.0071-08

Ferreira AA, Bustamante-Teixeira MT, Leite IC, Corrêa CS, Rodrigues Dde O, da Cruz DT. Clinical and functional evaluation of the joint status of hemophiliac adults at a Brazilian blood center. Rev Bras Hematol Hemoter. 2013;35(1):23-28. DOI: 10.5581/1516-8484.20130010

Martins RMB, et al. Infection with Hepatitis B virus in Hemophiliacs in Goiás: Seroprevalence, associated risk factors and vaccine response. Rev. Bras. Hematol. Hemoter. 2004;26(3):183-188.

CARAPEBA RAP. Características epidemiológicas dos portadores de hemofilia no Estado de Mato Grosso. 64f. Dissertação (Mestrado em Saúde Coletiva) - Programa de Pós-Graduação em Saúde Coletiva da Universidade Federal de Mato Grosso, Cuiabá; 2006.

Fontes EM, Amorim L, Carvalho SM, Farah MB. Hemophilia care in the state of Rio de Janeiro, Brazil. Rev Panam Salud Publica. 2003;13(2-3):124-128. DOI: 10.1590/s1020-49892003000200013

Rodrigues DOW, Santos OF, Esposito TS, Paz TMM, Rezende JD, Santos ACA, Rodrigues LOW. Coinfection by Hepatitis B, C and HIV in Patients with Hemophilia [abstract]. Res Pract Thromb Haemost. 2020;4(1).

Zhubi B, Mekaj Y, Baruti Z, Bunjaku I, Belegu M. Transfusion-transmitted infections in Hemophilia patients. Bosn J Basic Med Sci. 2009;9(4):271-277. DOI: 10.17305/bjbms.2009.2777

Arnold DM, Julian JA, Walker IR. Association of Hemophilia clinic directors of Canada. Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. Blood. 2006;108(2):460-464. DOI: 10.1182/blood-2005-11-4407

Meeks SL, Batsuli G. Hemophilia and inhibitors: Current treatment options and potential new therapeutic approaches. Hematology Am Soc Hematol Educ Program. 2016;2016(1):657-662. DOI:10.1182/asheducation-2016.1.657

Picanço-Castro V, Russo-Carbolante EM, Fontes AM, Fernandes AC, Covas DT. An enhancer/promoter combination strengthens the expression of blood-coagulation factor VIII in non-viral expression vectors. Genet Mol Res. 2008;7(2):314-325. DOI: 10.4238/vol7-2gmr447 Published 2008 Apr 8.

Brasil, Ministério da Saúde, Secretaria de Atenção à Saúde, Departamento de Atenção Especializada e Temática. Manual de Hemofilia – 2. ed., 1. reimpressão. – Brasília: Ministério da Saúde; 2015.

Brasil. Ministério da Saúde. Secretaria de Atenção à Saúde. Departamento de Atenção Hospitalar e de Urgência.Implantação e rotina dos testes de ácidos nucleicos (NAT) em serviços de hemoterapia – manual operacional 1. ed. – Brasília: Ministério da Saúde; 2013.

The Rotarian action group for Hepatitis Eradication and Rotary Club. Hepatitis Zero Project. Available:https://hepatitiszeroweek.com/pt-br/ Accessed on: Feb 15 2020.